An evaluation of artificial intelligence-based clinical decision supports use in Brazil.

Abstract

e18081 Background: The Instituto do Câncer do Ceará (ICC), a 160-bed oncology hospital located in Brazil, serves approximately 23,000 patients monthly. In December of 2017, ICC implemented Watson for Oncology (WFO), an artificial intelligence (AI)-based clinical decision-support (CDS) tool to help enhance personalized cancer care. As of December 2018, 903 cases involving mainly breast, prostate and gastric cancers were entered in WFO. The purpose of this study was to investigate how implementation of WFO and use by oncologists affects clinical decision-making and workflow. Methods: 7 oncologists who employed WfO during and after the patients’ first visit were recruited to complete a survey regarding usability, decision-making and workflow. The group consisted of 1 urologist, 3 gastric surgeons, 1 gynecologist, 1 breast surgeon, 1 head-neck surgeon. Survey questions integrated the CDS Five Rights framework. Results: Most oncologists agreed that WFO is easy to understand and provides complete, relevant and actionable information at an appropriate time (Table). Opinions on the impact on treatment decisions varied. 71.4% expressed positive statements (agree or strongly agree) pertaining to the use of WFO. Conclusions: In this study, oncologists felt WFO met 5 Rights expectations for CDS; 57% felt that WFO exceed expectations. Further research is needed to understand how variation in experience affects decision impact. [Table: see text]

Ähnliche Arbeiten